Literature DB >> 3181952

Cortical versus medullary thymomas: a useful morphologic distinction?

M J Kornstein1, W J Curran, A T Turrisi, J J Brooks.   

Abstract

We have tested the hypothesis that thymomas can be classified solely on the basis of epithelial cell morphology and that this distinction is prognostically useful. One hundred thymic epithelial tumors were classified according to the morphologic resemblance to cortical or medullary thymic epithelium and to the traditional classification (lymphocytic, epithelial, mixed, and spindled). Follow-up data was obtained on 78 patients. Fifty-eight percent of the tumors were invasive. Nineteen of the invasive tumors relapsed and none of the non-invasive tumors relapsed (P less than .0001). Four of nine tumors with microscopic invasion through the capsule recurred. Statistical analysis showed no significant differences in relapse-free survival for any of the histologic categories. Ninety-four percent of the tumors studied were keratin positive and all were chromogranin negative. Carcinoembryonic antigen was negative for all but one cytologically malignant tumor; of the tumors 75% were epithelial membrane antigen positive, 80% were Leu-7 positive, and 11% were neuron specific enolase positive. Seven of 12 tumors tested expressed HLA-DR. There was no correlation between immunoreactivity and classification. The morphologic cortical/medullary distinction is conceptually attractive but appears clinically to be no more advantageous than the traditional classification.

Entities:  

Mesh:

Year:  1988        PMID: 3181952     DOI: 10.1016/s0046-8177(88)80289-2

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

1.  Cells immunoreactive for neuropeptide in human thymomas.

Authors:  L Lauriola; N Maggiano; L M Larocca; F O Ranelletti; R Ricci; M Piantelli; A Capelli
Journal:  J Clin Pathol       Date:  1990-10       Impact factor: 3.411

Review 2.  Tumours of the thymus and their nomenclature.

Authors:  H F Otto
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

Review 3.  Thymomas. Current experience and future directions in therapy.

Authors:  P J Loehrer
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

Review 4.  Thymoma and thymic carcinoma.

Authors:  Federico Venuta; Erino A Rendina; Marco Anile; Tiziano de Giacomo; Domenico Vitolo; Giorgio F Coloni
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-01-13

5.  Clinical and pathologic predictors of survival in patients with thymoma.

Authors:  K B Wilkins; E Sheikh; R Green; M Patel; S George; M Takano; M Diener-West; J Welsh; S Howard; F Askin; G B Bulkley
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

6.  Observer variation in the histopathological classification of thymoma: correlation with prognosis.

Authors:  A Dawson; N B Ibrahim; A R Gibbs
Journal:  J Clin Pathol       Date:  1994-06       Impact factor: 3.411

Review 7.  [Standard outcome measures for thymic malignancies].

Authors:  James Huang; Frank C Detterbeck; Zuoheng Wang; Patrick J Loehrer
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.